Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

When ticks bite us, they release thousands of proteins through their saliva. Could a vaccine for the right ones stop ticks ...

TAMPA — Florida’s top health official blasted the manufacturer’s of mRNA COVID-19 vaccines and wants the federal government to do more to help those he described as the “vaccine injured.” Florida ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...

A new scientific study has found that Pfizer’s COVID-19 vaccine may cause temporary changes in the eyes’ corneal structure, ...

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...